Khamis Tomusange

Woodville Road, Woodville South
Adelaide, SA 5011, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis.

Development and characterization of AD-214, an anti-CXCR4 i-body-Fc fusion for the treatment of idiopathic pulmonary fibrosis.

Journal: mAbs

Published: May 21, 2025

Anti-HIV IgM protects against mucosal SHIV transmission.

Anti-HIV IgM protects against mucosal SHIV transmission.

Journal: AIDS (London, England)

Published: May 16, 2018

Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques.

Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques.

Journal: Journal of virology

Published: February 06, 2018

Human Rhinovirus-A1 as an Expression Vector.

Human Rhinovirus-A1 as an Expression Vector.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: April 05, 2017

Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.

Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.

Journal: British journal of pharmacology

Published: March 20, 2017

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.

Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.

Journal: Journal of medicinal chemistry

Published: February 04, 2017

Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses.

Mucosal vaccination with a live recombinant rhinovirus followed by intradermal DNA administration elicits potent and protective HIV-specific immune responses.

Journal: Scientific reports

Published: July 04, 2016

A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice.

A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice.

Journal: Scientific reports

Published: February 10, 2016

Engineering human rhinovirus serotype-A1 as a vaccine vector.

Engineering human rhinovirus serotype-A1 as a vaccine vector.

Journal: Virus research

Published: February 04, 2015

Showing 1-9 of 9

Last Updated: 09/26/2026